close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aridis Pharmaceuticals Inc. - Common Stock (NQ:ARDS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aridis Pharmaceuticals Inc. - Common Stock

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV
Via ACCESSWIRE
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Via ACCESSWIRE
FDA Provides Positive Feedback for Aridis Pharmaceuticals’ (NASDAQ: ARDS) AR-301 Phase 3 Study
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) receives encouraging input from the FDA for the proposed confirmatory Phase 3 trial of AR-301, 
Via Spotlight Growth
Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong
ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July... 
From RedChip
Via AccessWire
Medical Breakthrough: CRISPR Gene Editing Technology from MIT and Harvard Phase 3: Aridis Pharmaceuticals (Nasdaq: ARDS)
NASDAQ Co. Focused on CRISPR Gene Editing Technology from the Broad Institute of MIT and Harvard: Aridis Pharmaceuticals, Inc. (Stock Symbol: ARDS) 
Via EIN Presswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today